Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes

Leukemia Research

Volumn 38, Issue 1, 2014, Pages 29-33

  Prebet, Thomas ^a   Braun, Thorsten ^b   Beyne Rauzy, Odile ^c   Dreyfus, Francois ^d   Stammatoullas, Aspasia ^e   Wattel, Eric ^f   Ame, Shanti ^g   Raffoux, Emmanuel ^h   Delaunay, Jacques ⁱ   Charbonnier, Aude ^a   Adès, Lionel ^b   Fenaux, Pierre ^b   Vey, Norbert ^a  

^a INSTITUT PAOLI CALMETTES   (France)

^b AVICENNE HOSPITAL   (France)

^c CHU PURPAN   (France)

^d Centre Henri Becquerel ^*  (France)

^e CENTRE HENRI BECQUEREL   (France)

^f Hematology Department   (France)

^g UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^h SAINT LOUIS HOSPITAL   (France)

ⁱ NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

Azacitidine failure; Epigenetic; HDAC; Myelodysplasia

Indexed keywords

AZACITIDINE; BILIRUBIN; CYTARABINE; LIVER ENZYME; VORINOSTAT;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BILIRUBIN BLOOD LEVEL; BLAST CELL; BLEEDING; CLINICAL ARTICLE; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOPENIA; DIARRHEA; DISEASE COURSE; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ENZYME BLOOD LEVEL; ERYTHROCYTE TRANSFUSION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; GENE DELETION; GENETIC RISK; HEMATOLOGIC DISEASE; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; INFECTION; LOW DRUG DOSE; MALE; MIDDLE AGED; MONOSOMY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RELAPSE; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TRISOMY; UNSPECIFIED SIDE EFFECT; VERY ELDERLY; VOMITING;

EID: 84890558746     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.07.023     Document Type: Article

References (23)

1. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088.
2. Silverman L.R., Demakos E.P., Peterson B.L., Kornblith A.B., Holland J.C., Odchimar-Reissig R., et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002, 20:2429-2440.
3. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., Santini V., Finelli C., Giagounidis A., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009, 10:223-232.
4. Prebet T., Gore S.D., Esterni B., Gardin C., Itzykson R., Thepot S., et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol 2011, 29:3322-3327.
5. Esteller M. Epigenetics in cancer. N Engl J Med 2008, 358:1148-1159.
6. Sanchez-Gonzalez B., Yang H., Bueso-Ramos C., Hoshino K., Quintas-Cardama A., Richon V.M., et al. Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor. Blood 2006, 108:1174-1182.
7. Cameron E.E., Bachman K.E., Myohanen S., Herman J.G., Baylin S.B. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999, 21:103-107.
8. Park M.A., Zhang G., Martin A.P., Hamed H., Mitchell C., Hylemon P.B., et al. Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation. Cancer Biol Ther 2008, 7:1648-1662.
9. Kelly W.K., O'Connor O.A., Krug L.M., Chiao J.H., Heaney M., Curley T., et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005, 23:3923-3931.
10. O'Connor O.A., Heaney M.L., Schwartz L., Richardson S., Willim R., MacGregor-Cortelli B., et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 2006, 24:166-173.
11. Prebet T., Vey N. Vorinostat in acute myeloid leukemia and myelodysplastic syndromes. Expert Opin Invest Drugs 2011, 20:287-295.
12. Garcia-Manero G., Yang H., Bueso-Ramos C., Ferrajoli A., Cortes J., Wierda W.G., et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008, 111:1060-1066.
13. Vardiman J.W., Thiele J., Arber D.A., Brunning R.D., Borowitz M.J., Porwit A., et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009, 114:937-951.
14. Cheson B.D., Greenberg P.L., Bennett J.M., Lowenberg B., Wijermans P.W., Nimer S.D., et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006, 108:419-425.
15. Shiozawa K., Nakanishi T., Tan M., Fang H.B., Wang W.C., Edelman M.J., et al. Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias. Clin Cancer Res 2009, 15:1698-1707.
16. Prebet T., Gore S.D., Thepot S., Esterni B., Quesnel B., Rauzy O.B., et al. Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure. Br J Haematol 2012.
17. Schaefer E.W., Loaiza-Bonilla A., Juckett M., DiPersio J.F., Roy V., Slack J., et al. A phase 2 study of vorinostat in acute myeloid leukemia. Haematologica 2009, 94:1375-1382.
18. Chomienne C., Najean Y., Degos L., Thomas G., Baumelou E., Calvo F., et al. Present results of the treatment of myelodysplastic syndromes with low-dose cytosine arabinoside. Preliminary results of a cooperative protocol (38 patients) and review of the literature. Acta Haematol 1987, 78(Suppl. 1):109-115.
19. Burnett A.K., Milligan D., Prentice A.G., Goldstone A.H., McMullin M.F., Hills R.K., et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 2007, 109:1114-1124.
20. Faderl S., Garcia-Manero G., Jabbour E., Ravandi F., Borthakur G., Estrov Z., et al. A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. Cancer 2012, 118:722-728.
21. Braun T., Raffoux E., Prebet T., Brechignac S., Stamatoullas A., Dreyfus F., et al. Low-dose clofarabine has significant activity in high-risk myelodysplastic syndromes (MDS) and acute myeloid leukemia post-MDS (sAML) after azacitidine (AZA) failure: interim results of the GFM Clo08 dose escalating phase I/II study (NCT0106325). Blood (ASH Annual Meeting Abstracts) 2011.
22. Kantarjian H., Garcia-Manero G., O'Brien S., Faderl S., Ravandi F., Westwood R., et al. Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome. J Clin Oncol 2010, 28:285-291.
23. Seetharam M., Fan A.C., Tran M., Xu L., Renschler J.P., Felsher D.W., et al. Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na. Leukemia Res 2012, 36:98-103.